Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Creative Biolabs offers assay services of evaluating the stability of TCR/CD3 complex to ensure the harvest of high quality TCR-modified T cells. The effective interaction of CD3 with TCR and the ξ-chain is required for the generation of activation signal in T lymphocytes. Increased stability of the TCR/CD3complex contributes to the enhanced antitumor response activity of T cells. At Creative Biolabs, the TCR/CD3 complex stability assay can be achieved via immunoprecipitation and immunoblot.
T-cells are a subset of lymphocytes that play a large role in the immune response targeting to various antigens. When T lymphocytes encounter antigens via the T cell antigen receptor (TCR), information about the quantity and quality of antigen engagement is relayed to the intracellular signal transduction machinery, but the TCR itself lacks a significant intracellular domain, resulting in lacking signal transduction ability. Therefore, it is usually associated with CD3 molecules which contain intracellular signaling domains to couple the TCR/CD3 complex as the downstream signaling machinery. The TCR/CD3 complex, also known as the TCR complex, is composed of six subunits which are expressed on the cell surface in a coordinate pattern after assembly in the endoplasmic reticulum (ER). The TCR/CD3 complex is assembled after a series of pairwise interactions involving the formation of dimmers of CD3 epsilon (CD3ε) with either CD3 gamma (CD3γ) or CD3 delta (CD3δ). These dimmers assemble with TCR alpha (TCR α )and TCR beta (TCRβ) chains, and finally, the CD3ξ (CD3 zeta) homodimer is added to allow export of the full complex from the ER. The main task of the TCR/CD3 complex includes two parts: ligand recognition and signal transduction from infectious agents. And it divides the tasks among its different components. In detail, the TCR contain variable regions and are responsible for antigen/MHC recognition; while the other four CD3ε, CD3γ, CD3δ and CD3ξ-chain are invariable and contain long cytoplasmic tails capable of interacting with the intracellular signal transduction machinery. Since the TCR-CD3 complex serves a critical role in the differentiation, survival, and function of T cells, and receptor triggering elicits a complex set of biological responses that serve to protect the organism from infectious agents, it is of great importance to study the TCR/CD3 complex stability of TCR-modified T cells in order to achieve an effective disease-targeting therapy.
With full understanding of the TCR/CD3 complex, Creative Biolabs is committed to offering high-standard TCR/CD3 stability assay to every client. If you have any special question about the issues of TCR products and services, please contact our scientists for help.
To discuss your demands or to request a proposal, please contact us by .
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
